Connect Biopharma Holdings Limited Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
Connect Biopharma Holdings Limited (CNTB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 278.40 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2026-08-12
- Connect Biopharma Holdings Limited share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2026-06-30 was 14.60K shares, a 98.29% decline year-over-year.
- Connect Biopharma Holdings Limited share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2026-03-31 was 263.80K shares, a 4.68% increase year-over-year.
- Connect Biopharma Holdings Limited share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2025-12-31 was 2.68M shares.
- Connect Biopharma Holdings Limited share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2025-09-30 was 273.50K shares.
- Connect Biopharma Holdings Limited share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2025 was 4.06M shares, a 61.45% decline from fiscal 2024.
- Connect Biopharma Holdings Limited share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2024 was 10.53M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|---|---|---|
| 2026-06-30 | 14.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 278.40K shares 10-Q · filed 2026-08-12 | 2.96M shares derived: sum of 3 quarters · filed 2026-08-12 | 3.23M shares derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 263.80K shares 10-Q · filed 2026-05-12 | 2.95M shares derived: sum of 2 quarters · filed 2026-05-12 | 3.22M shares derived: sum of 3 quarters · filed 2026-05-12 | 4.07M shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 2.68M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 2.95M shares derived: sum of 2 quarters · filed 2026-03-31 | 3.81M shares derived: sum of 3 quarters · filed 2026-03-31 | 4.06M shares 10-K · filed 2026-03-31 |
| 2025-09-30 | 273.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 1.13M shares derived: sum of 2 quarters · filed 2025-11-12 | 1.38M shares 10-Q · filed 2025-11-12 | |
| 2025-06-30 | 852.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | 1.10M shares 10-Q · filed 2025-08-13 | ||
| 2025-03-31 | 252.00K shares 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | 10.53M shares 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |